UNASSIGNED: 877 Background: @entity136 is an active drug in @entity0 : 37% of responses as first line, 26% as a second line and 18% as tirad line; The responses with @entity136 plus @entity900 is @entity1 with MBC is: 40% to 80%. @entity3003 has not been identified as active drug in @entity0 , however @entity136 hs an wide synergism with this drug. METHODS: The aim of this study was to evaluate the efficacy and security of the chemotherapy with @entity136 and @entity3003 in recurrent @entity0 . All @entity1 had clinically and by scan CT, measurable disease. TREATMENT: @entity136 1000 mg/m2 days 1 and 8, @entity3003 AUC 5 day 1, Cycles repeated q21 days as blood count permitted until limited @entity137 or progression. RESULTS: 19 @entity1 were treated with palliative chemotherapy with GC, and there were 69 courses of chemotherapy. All pts received @entity8253 , FAC 15 pts, @entity4757 pt and 3 pts combined with @entity6023 in adjuvant setting; all received radiotherapy after adjuvant chemotherapy and all received also hormonal therapy in adjuvant setting. All pts received @entity6023 in recurrence and between 2 and 4 chemotherapy schedules that included: @entity416 , other @entity6023 , @entity1206 , @entity1487 and @entity900 . Median age was 44.5 years. 15 pt had ductal adencarcinoma and 2 pts had @entity189 . . Stage II: 6 @entity1 and stage III-IV: 12 @entity1 ; median follow-up was 5.2 (3.4-10.8 mo). Objective Responses (OR) were presented in 4 pt (21.5%); CR 2 pt, PR 2 pt and Stable disease 8 pts; @entity74 ( @entity74 ) in 7 pts (31.3%); the responses were two locally and two more in the @entity3 (hepatic). Median overall survival was 7.5 mo. The current status is 4 pts alive without tumoral activity (18.7%), 12 pts alive with tumoral activity (62.6%), and 3 dead pts with tumoral activity (18.7%). Related to @entity137 was presented in 4 pts (5.79%), @entity1210 in 3 pts (4.34%), @entity1398 in 4 pts (5.79%) and @entity882 in 1 pt (1.44%). CONCLUSION: @entity136 plus @entity3003 is an active combination (11 OR), this scheme is of an easy administration, and very well tolerated in @entity1 with metastatic and recurrent @entity0 , must be considered as an option in the metastatic setting. No significant financial relationships to disclose.

@entity136 plus XXXX in recurrent and @entity0 : A phase II trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicity anemia'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['lobulillar carcinoma'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'Progression disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity4757 :: ('6863', 'Gene') :: ['Tac 1'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5FU'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['Leucopenia']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
